UK Markets closed
  • NIKKEI 225

    26,402.84
    -508.36 (-1.89%)
     
  • HANG SENG

    20,120.68
    -523.60 (-2.54%)
     
  • CRUDE OIL

    109.78
    +0.19 (+0.17%)
     
  • GOLD FUTURES

    1,841.20
    +25.30 (+1.39%)
     
  • DOW

    31,165.81
    -324.26 (-1.03%)
     
  • BTC-GBP

    24,152.66
    +736.46 (+3.15%)
     
  • CMC Crypto 200

    672.02
    +19.79 (+3.03%)
     
  • Nasdaq

    11,417.81
    -0.35 (-0.00%)
     
  • ^FTAS

    4,038.94
    -71.55 (-1.74%)
     

Unaudited NAV for April

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Arix Bioscience PLC (ARIX)
Unaudited NAV for April
11-May-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

PRESS RELEASE

Arix Bioscience plc

 

Unaudited NAV for April

 

LONDON, 11 May 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited NAV of the Company for date ended 30 April 2022 as follows:

 

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

30-Apr-22

(unaudited)

£36.3m

£57.7m

£132.6m

£2.8m

£229.4m

 

£1.78

 

 

[ENDS]

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:

GB00BD045071

Category Code:

NAV

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

160805

EQS News ID:

1348823


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting